EFFECT OF FLUMAZENIL ON BASAL AND NALOXONE‐STIMULATED ACTH AND CORTISOL RELEASE IN HUMANS

1. Endogenous benzodiazepine receptor ligands are thought to influence the human hypo‐thalamic‐pituitary‐adrenal (HPA) axis and naloxone, a known stimulator of adrenocorticotropic hormone (ACTH) release, is thought to act via release of hypothalamic corticotropin‐releasing hormone.

[1]  D. Torpy,et al.  Alprazolam blocks the naloxone-stimulated hypothalamo-pituitary-adrenal axis in man. , 1993, The Journal of clinical endocrinology and metabolism.

[2]  A. Guidotti,et al.  Endogenous benzodiazepine receptor ligands in idiopathic recurring stupor , 1992, The Lancet.

[3]  D. Orth.  Corticotropin-releasing hormone in humans. , 1992, Endocrine reviews.

[4]  J. Bormann.  Electrophysiological characterization of diazepam binding inhibitor (DBI) on GABAA receptors , 1991, Neuropharmacology.

[5]  J. Grice,et al.  Adrenocorticotropin Hyperresponsiveness in Myotonic Dystrophy Following Oral Fenfluramine Administration , 1991, Journal of neuroendocrinology.

[6]  A. Guidotti,et al.  Diazepam binding inhibitor (DBI): a peptide with multiple biological actions. , 1991, Life sciences.

[7]  G. Chrousos,et al.  In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications. , 1990, The Journal of clinical endocrinology and metabolism.

[8]  J. Grice,et al.  NALOXONE‐INDUCED ACTH RELEASE IN MAN IS INHIBITED BY CLONIDINE , 1990, Clinical and experimental pharmacology & physiology.

[9]  P. Meier,et al.  Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. , 1989, Gastroenterology.

[10]  A. Guidotti,et al.  Cerebrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy , 1989, Annals of neurology.

[11]  D. Pickar,et al.  Diazepam binding inhibitor and corticotropin releasing hormone in cerebrospinal fluid , 1989, Biological Psychiatry.

[12]  G. Chrousos,et al.  Interaction between GABAergic neurotransmission and rat hypothalamic corticotropin-releasing hormone secretion in vitro , 1988, Brain Research.

[13]  R. N. Brogden,et al.  Flumazenil. A preliminary review of its benzodiazepine antagonist properties, intrinsic activity and therapeutic use. , 1988, Drugs.

[14]  J. Meador-Woodruff,et al.  Effects of psychotropic medications on hypothalamic-pituitary-adrenal regulation. , 1988, Endocrinology and metabolism clinics of North America.

[15]  C. Barb,et al.  On the site of action of naloxone-stimulated cortisol secretion in gilts. , 1988, Life sciences.

[16]  G. Stalla,et al.  The role of CRF in the release of ACTH by opiate agonists and antagonists in rats , 1987, Brain Research.

[17]  P. Plotsky,et al.  Neurotransmitter modulation of corticotropin releasing factor secretion into the hypophysial-portal circulation. , 1987, Life sciences.

[18]  S. Paul,et al.  Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease. , 1986, Archives of general psychiatry.

[19]  W. Nicholson,et al.  Rapid radioimmunoassay for corticotropin in unextracted human plasma. , 1984, Clinical chemistry.

[20]  J. Volavka,et al.  Naloxone increases ACTH and cortisol levels in man. , 1979, The New England journal of medicine.

[21]  M. Jones,et al.  Effect on various putative neurotransmitters on the secretion of corticotrophin-releasing hormone from the rat hypothalamus in vitro-a model of the neurotransmitters involved. , 1976, The Journal of endocrinology.